First Patient Randomized in Phase 2 Trial to Assess Efficacy

Although still recruiting, the first patient was randomized to receive NBI-1070770 for major depressive disorder in a phase 2 trial assessing efficacy, safety, and tolerability.

Related Keywords

United States , Neurocrine Biosciences , Eiryw Roberts , Depression Rating Scale , Biosciences Announces First Patient Dosed , Study Evaluating , Major Depressive ,